Abstract | BACKGROUND: Improved outcome for children with medulloblastoma requires new treatment protocols which incorporate chemotherapeutic agents that are capable of eradicating minimal residual disease in the primary posterior fossa site and in the leptomeninges and whose toxicities are tolerable. PROCEDURE: RESULTS: The estimated 3-year progression-free survival (PFS) was 0.73 (S.E. +/- 0.09) compared with a 3-year PFS of 0.69 in historical controls treated with surgical resection and CSRT but without chemotherapy. Six relapses occurred outside the posterior fossa and one relapse occurred both in the posterior fossa and in the lateral ventricle. The major acute toxicities were myelosuppression, anorexia and neuropathy. CONCLUSIONS:
|
Authors | I Bergman, R I Jakacki, G Heller, J Finlay |
Journal | Medical and pediatric oncology
(Med Pediatr Oncol)
Vol. 29
Issue 6
Pg. 563-7
(Dec 1997)
ISSN: 0098-1532 [Print] United States |
PMID | 9324345
(Publication Type: Clinical Trial, Journal Article, Multicenter Study)
|
Chemical References |
|
Topics |
- Adolescent
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Carboplatin
(administration & dosage)
- Cerebellar Neoplasms
(therapy)
- Child
- Child, Preschool
- Combined Modality Therapy
- Cranial Irradiation
- Disease-Free Survival
- Female
- Humans
- Male
- Medulloblastoma
(therapy)
- Radiotherapy Dosage
- Vincristine
(administration & dosage)
|